Solaxa, with a valuation of $15 million, is raising funds on Wefunder. The company is revolutionizing the treatment of nerve dysfunction with its FDA-approved drug. The company is clinical-stage ready and neuro-focused and is developing better treatments for hereditary ataxias and nerve injury. The drug targeting nerve dysfunction caused by hereditary ataxia is called Ampyra or dalfampridine and is already FDA-approved to improve walking in adults with multiple sclerosis. Christian Walker founded Solaxa in February 2021. The current crowdfunding campaign has a minimum target of $50,000 and a maximum target of $1.2 million. The campaign proceeds will be used for salaries, consulting and legal services to obtain orphan drug designation, pre-clinical research and development, product development and manufacturing, and company operations.